BY THE OPTIMIST DAILY EDITORIAL TEAM
Imagine replacing a daily pill with just two injections a year. That is now a reality in Europe, where the European Commission has approved the first twice-yearly shot to prevent HIV. The drug, lenacapavir, marketed as Yeytuo, is already being hailed as a turning point in public health.
In clinical trials, the medicine proved 100 percent effective in preventing HIV transmission. For experts, that makes it one of the most striking breakthroughs of 2024, and one with very practical implications. Daily adherence to medication has long been a barrier in prevention. Cutting that to two visits per year could make protection far more accessible.
A timely intervention
The decision comes against a backdrop of rising HIV cases. In 2023 alone, more than 24,700 people were newly diagnosed across the EU, Iceland, Liechtenstein, and Norway. This is an increase of nearly 12 percent over the previous year. Public health advocates warn that prevention tools must keep pace if Europe hopes to reverse that trend.
“This underscores the transformative potential of Yeytuo,” said Dr. Dietmar Berger, chief medical officer at Gilead Sciences, the company behind the drug. The European Commission’s quick approval, just a month after the European Medicines Agency recommended it, signals how urgent the need has become.
From Brussels to beyond
The green light means Yeytuo will soon be available across EU countries as well as in Norway, Iceland, and Liechtenstein. Regulatory approvals are also moving forward elsewhere: the U.S. Food and Drug Administration has signed off, and applications are in progress in Australia, Brazil, Canada, South Africa, Switzerland, Argentina, Mexico, and Peru. The World Health Organization has endorsed the shot as another option in the prevention toolkit.
To widen global access, Gilead has agreed to permit generic production in 120 lower-income countries where HIV remains widespread. But equitable rollout is not guaranteed. Cuts to U.S. global health funding earlier this year cast doubt on how quickly the shot can reach communities that need it most.
An opportunity to close gaps
Globally, HIV still affects 40.8 million people, and 630,000 lives were lost last year to AIDS-related illnesses. Public health experts stress that while Yeytuo will not eliminate the epidemic overnight, it has the potential to change the calculus of prevention as long as governments and donors commit to equitable access.
The twice-yearly shot represents more than convenience. It is a reminder that solutions are within reach, but they depend on political will and sustained investment. With Europe now leading on rollout, the next chapter will be defined by how widely and fairly this innovation is shared.
